Eisai
Japan’s 2025 Bioindustry Awards: From Alzheimer’s Treatments to Regenerative Medicine, the Nation Charts Its Next Biotech Course
2025-10-16
Leqembi Makes History as First EU-Approved Drug to Target Root Cause of Alzheimer’s Disease
2025-04-15
FDA Granted Eisai and Biogen’s New Alzheimer’s Drug a Traditional Approval, Making Medicare Coverage Possible
2023-07-11
Biogen Concludes $900 Million Settlement Before Posting Positive Data From Alzheimer’s Trial
2022-09-28
LATEST
EVENT
2026-08-07
Healthy Ageing Tech Show (7-9 Aug, TAIPEI WTC) (Longevity, elder care & ageing tech)
Taipei, Taiwan







